The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...
VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for ...
SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART ® ...
Please provide your email address to receive an email when new articles are posted on . Psoriasis patients who self-administer bimekizumab experienced similar levels of comfort and success with both ...
The US Food and Drug Administration (FDA) has approved a prefilled syringe for self-injection of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) in the treatment of adults with ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results